Monarch Partners Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Monarch Partners Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-9,943	Closed	-$1.23M	–	190
2018 Q4	$1.23M	Sell	9,943 -47,197	-83%	-$7M	0.18%	95
2018 Q3	$9.61M	Buy	57,140 +85	+0.1%	+$14.6K	0.87%	48
2018 Q2	$9.83M	Buy	+57,055	New	+$9.33M	0.89%	46
2017 Q4	–	Sell	-41,360	Closed	-$6.05M	–	197
2017 Q3	$6.05M	Sell	41,360 -30,837	-43%	-$4.66M	0.58%	70
2017 Q2	$11.2M	Buy	72,197 +12,022	+20%	+$1.84M	1.11%	27
2017 Q1	$8.73M	Buy	+60,175	New	+$7.84M	0.88%	45

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Monarch Partners Asset Management's JAZZ Position: Q1 2019 in Review

Monarch Partners Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2019, closing a stake of 9,943 shares — an estimated $1.23M sold.

Monarch Partners Asset Management first reported a position in JAZZ in Q1 2017 and held it in 6 quarters. The position peaked at $11.2M in Q2 2017. 427 funds tracked by Wall St. Rank hold JAZZ as of Q1 2019.

Monarch Partners Asset Management reported no remaining Jazz Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Monarch Partners Asset Management sold 9,943 Jazz Pharmaceuticals shares in Q1 2019, an estimated $1.23M.
Monarch Partners Asset Management first reported a position in Jazz Pharmaceuticals in Q1 2017 and held it in 6 quarters.
Monarch Partners Asset Management's Jazz Pharmaceuticals position peaked at $11.2M in Q2 2017.
427 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2019.

Based on Monarch Partners Asset Management's 13F filing for Q1 2019, filed 9 May 2019.